Abstract:Tumorogenesis is characterized by the unregulated proliferation of cells, which is the consequence of dysregulated cell division mechanisms. To ensure the rapid multiplication and invasion, tumor tend to create unique tumor microenvironment (TME) benefiting its own progression. As abnormal component in the body, figuring out how to escape from the supervision and attack of immune system is the key of tumor survival. Angiogenesis, which is mainly triggered by the stimulation of vascular endothelial growth factor (VEGF), is one of its solutions. Characterized by hypoxia, most type of tumor cells significantly upregulate VEGF, which stimulates active construction of tumor neovascularization. [1][2][3] However, the newly-formed tumor blood vessels show series of abnormalities, including increased luminal resistance, increased endothelial permeability and limited blood flow caused by defects in structure. [4] The features above are beneficial to the tumor growth and metastasis, as well as immune evasion, inducing resistance to immunotherapy. It was reported that anti-angiogenesis therapy has been seen as a promising strategy to enhance tumor immune response, which contributes to improve immunosuppressive TME and helps with anti-tumor effects by immune system. [5][6][7] The relation between angiogenesis and immune response was revealed in gene and transcriptomic level. Kurmyshkina et al. focused on the difference of transcriptomic landscapes between early-stage invasive cervical carcinoma (CeCa) and cervical intraepithelial neoplastic lesions (CIN). The authors found that innate immune pathways in early-stage CeCa were significantly upregulated in response to the infection of human papillomavirus, compared with CIN as precursor lesions. The tumors with active immune infiltration showed a more differentiated phenotype, while the ones with increased expression of genes associated with angiogenesis were related to exacerbation of de-differentiation and epithelial-to-mesenchymal transition. As reported, anti-angiogenesis therapy was expected to improve immune evasion and enhance immune infiltration. Shafqat et al. summarized previous studies which focused on tumor angiogenesis and coagulation exert suppressive effects on anti-tumor immune response. Both of them mediates the impacts above through specific mechanisms ultimately leading to the reprogramming of TME. Whether the usage of anti-angiogenic therapies to achieve vascular normalization and ACEi/ARBs to achieve stromal normalization targeting angiogenesis, or anticoagulants targeting coagulation, showed similar result of limit tumor progression and transform TME to favor immune response against tumors. Also, they both demonstrated the efficacy of enhance immunotherapy while combining with ICIs, despite the heterogeneity of tumor types still needs to be considered in the conjunction. It is natural to associate angiogenesis with prognosis since its influence on tumor invasion and progression. Li et al. developed an advanced machine learning model to evaluate the prognosis and therapy response of breast cancer based on several genes related to vascular mimicry (VM), the performance of which continuously exceeds that of traditional ones. The tumor group received higher VM scores than the normal group. The high-risk group showed higher level of tumor mutation burden (TMB) and higher mutation rate of tumor suppressor genes, and higher level of immune escape suggesting poor response to immunotherapy at the same time. Meanwhile, the low-risk group appeared more favorable response to immune checkpoint blockage. Eventually, the authors identified several promising chemotherapy drugs to which was VM related genes sensitive.To summarize, the studies above introduce some latest advances in the roles of angiogenesis and immune response in TME of solid tumors, and hopefully contribute to the further explorations of immunotherapy enhancer. We would like to acknowledge the invaluable support of all authors, reviewers and the editor team during the topic preparation process. We are looking forward to significant breakthroughs in the approach of sensitizing immunotherapy through anti-angiogenesis agents to emerge soon.

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature.

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

Spatially Resolved Analyses Link Genomic and Immune Diversity and Reveal Unfavorable Neutrophil Activation in Melanoma

Abstract 6872: A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

492 Integration of High Dimensional Datasets in an Immunocompetent Mammary Mouse Model Reveals Pathways of Tolerance and Resistance to Immune Checkpoint Blockade

Modelling the tumor immune microenvironment for precision immunotherapy

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Understanding the tumor immune microenvironment (TIME) for effective therapy

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Abstract 1154: Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response

Abstract 2486: Dissecting tumor-immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma

Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies